Telehealth companies like Hims & Hers (HIMS) are aggressively marketing hair-loss medications to young men, with some patients saying they ...

Hims and other telehealth firms make finasteride easy to get and don’t have to disclose side effects in ads.

Roller-coaster healthcare stock Hims & Hers Health ( HIMS -1.34%), whose stock got devastated last week by worries that it ...

Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...

Apostrophe, a Bay Area telehealth company focused on skin care, shut down after almost four years under the Hims & Hers ...

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

News About the Weight-Loss Drugs Is Pressuring HIMS Stock Eli Lilly disclosed today that it had started selling 7.5 milligram and 10 milligram vials of Zepbound, its popular weight-loss drug, for ...

Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular weight-loss drugs today. Additionally, the FDA last week hindered the ...

Hims & Hers (HIMS) stock plunged 27% on Tuesday after the telehealth highflier indicated it may soon stop offering some compounded versions of weight-loss drugs. The company's fourth quarter ...

Stock in Hims & Hers Health was bound to tumble once it could no longer sell compounded versions of the weight-loss drug Wegovy at scale. But with lofty expectations about its remaining anti ...

Direct-to-consumer telehealth company Hims & Hers is forging ahead in the aftermath of the semaglutide shortage ending last week. Hims & Hers faces new headwinds in its weight management segment ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended trading. Revenue increased 95% from a year earlier to $481 million ...